New Research Shows Oncotype DX® Breast Cancer Test Helps Reduce Burden of Chemotherapy
Yahoo! Finance USA,
Research Including Patients from Quebec Demonstrated Significant Impact of Genomic Health's Oncotype DX® in Personalizing…
Showing items 1–100
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WTOL,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KTEN,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WTOC,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WMC Action News 5,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
South Carolina News Now,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WTVM,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Mississippi News Now ,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WMBF News,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Fox 14 News,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KUSI News,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KSLA News 12,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
2 News,
Information contained on this page is provided by an independent third-party content provider.
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
NewsOn6,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Ticker Tech,
/PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
CW: Richmond,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WRCB- TV,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
NBC12,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
14 News,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KLTV,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
News Channel 6,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WDRB,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Ariva,
/PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
NewsWest9,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KHQ,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
News 9,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
ABC 7 News KSWO,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WBOC 16,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Cleveland 19,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Benzinga,
A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low Oncotype DX Breast Recurrence…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
CBS8,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WDAM - TV,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KTRE,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WFMJ,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KAIT-TV,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Kuam,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
NBC Right Now KNDU 25,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
48 WAFF,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WSFA ,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WISTV,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WLOX,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KFVE The Home Team,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KLKN-TV Eyewitness News,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Wave 3 News,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
News Channel,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
KPLC 7 News,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WALB,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WAND 17,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
WFLX Fox 29,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Hawaii News Now,
SOURCE Genomic Health, Inc. A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
PR Newswire,
A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low Oncotype DX Breast Recurrence…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Yahoo! Finance USA,
/PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced the publication of results from the National Cancer Institute's (NCI…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
NASDAQ,
/PRNewswire/ -- Genomic Health, Inc. (Nasdaq:GHDX) today announced the publication of results from the National Cancer Institute…
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
Bioportfolio,
REDWOOD CITY, Calif., March 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of…
Genomic Health Release Published Outcomes Results From SEER Registries Indicates That Many Node Positive Breast Cancer Patients Can Avoid Chemotherapy
Device Space,
REDWOOD CITY, Calif., March 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of…
Genomic Health Release: Published Outcomes Results From SEER Registries Indicates That Many Node-Positive Breast Cancer Patients Can Avoid Chemotherapy Based On Oncotype DX Results
Biospace,
/PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
News Channel 6,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WRCB- TV,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
KTEN,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
Kuam,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
KLTV,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WTOC,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WDRB,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
KAIT-TV,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WDAM - TV,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
NewsWest9,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WFMJ,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
Mississippi News Now ,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
2 News,
Information contained on this page is provided by an independent third-party content provider.
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WMBF News,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
Ariva,
PR Newswire REDWOOD CITY, Calif., March 20, 2017 REDWOOD CITY, Calif., March 20, 2017 /PRNewswire/ -- Genomic Health, Inc.
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
KTRE,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WTVM,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
KSLA News 12,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
ABC 7 News KSWO,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
KUSI News,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
NewsOn6,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
14 News,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WMC Action News 5,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
CW: Richmond,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
South Carolina News Now,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
NBC12,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WBOC 16,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
CBS8,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
KHQ,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WTOL,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WAND 17,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WSFA ,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
News Channel,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
48 WAFF,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WLOX,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
Wave 3 News,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
KPLC 7 News,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
Cleveland 19,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
KFVE The Home Team,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
Fox 14 News,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
WALB,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
NBC Right Now KNDU 25,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
Hawaii News Now,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
News 9,
SOURCE Genomic Health, Inc. New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy…
Showing items 1–100